Stereotactic Ablative Radiation Therapy for Oligo-Progressive Disease REfractory to Systemic Therapy in Head and Neck Cancer

Official Title

Stereotactic Ablative Radiation Therapy for Oligo-Progressive Disease REfractory to Systemic Therapy in Head and Neck Cancer: A Phase II Randomized Trial

Summary:

A registry-based randomized phase II trial. A total of 46 patients with metastatic head and neck cancer on systemic therapy with oligoprogression to 1-5 extracranial lesions will be randomized using a 1:1 ratio to standard of care (begin next-line systemic therapy, best supportive care, continue current systemic line, based on treating physician decision) vs. receive stereotactic ablative radiation therapy to all oligoprogressive lesions while continuing their current systemic therapy.

Trial Description

Primary Outcome:

  • Progression free survival
Secondary Outcome:
  • Overall survival
  • Quality of life Measured using the FACT-G tool, head and neck cancer-related patient reported outcome- CTCAE (PRO-CTCAE) and Quality of life 5-level EQ-5D
  • Grade ≥ 3 toxicity Measured using the Common Terminology Criteria for Adverse Events (CTCAE v5.0)
  • Local control
  • Time to next systemic therapy

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society